TY - JOUR
T1 - VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma
AU - Sinha, Sutapa
AU - Cao, Ying
AU - Dutta, Shamit
AU - Wang, Enfeng
AU - Mukhopadhyay, Debabrata
PY - 2010/3
Y1 - 2010/3
N2 - Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.
AB - Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.
KW - Mice model
KW - Renal cell carcinoma
KW - Vinorelbine and 2C3
UR - http://www.scopus.com/inward/record.url?scp=77953490722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953490722&partnerID=8YFLogxK
U2 - 10.1111/j.1582-4934.2008.00578.x
DO - 10.1111/j.1582-4934.2008.00578.x
M3 - Article
C2 - 19017359
AN - SCOPUS:77953490722
SN - 1582-1838
VL - 14
SP - 647
EP - 658
JO - Journal of Cellular and Molecular Medicine
JF - Journal of Cellular and Molecular Medicine
IS - 3
ER -